Rheumatoid arthritis

References

• Harris ED. The clinical features of rheumatoid arthritis. In: Kelley WN. Textbook of rheumatology. 3d ed. Philadelphia: WB Saunders, 1989: 943–81
   Google Scholar
• Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978: 298(16): 869–71
   PubMed Web of Science ®Google Scholar
• Cooperating Clinics of the New York Chapter of the Arthritis Foundation. A retrospective look at prescribing practice to NSAIDs in rheumatoid arthritis. (Abstr) In: Proceedings of Eighth Pan-American Congress of Rheumatology, San Francisco. 1982 Jun 7
   Google Scholar
• Furst DE, Blocka K, Cassell S, et al. A strategy for reaching therapeutic salicylate levels in patients with rheumatoid arthritis using standardized dosing regimens. J Rheumatol 1987: 14(2): 342–7
   PubMed Web of Science ®Google Scholar
• Day RO, Furst DE, Dromgoole SH, et al. Changes in salicylate serum concentration and metabolism during chronic dosing in normal volunteers. Biopharm Drug Dispos 1988: 9(3): 273–83
   PubMed Web of Science ®Google Scholar
• Paulus HE. Aspirin versus nonacetylated salicylate. (Editorial) J Rheumatol 1989: 16(3): 264–5
   PubMed Web of Science ®Google Scholar
• Szczeklik A. Analgesics, allergy and asthma. Br J Clin Pharmacol 1980: 10(Suppl 2): 401–5S
   Google Scholar
• Paulus HE, Furst DE. Aspirin and other non-steroidal anti-inflammatory drags. In: McCarty DJ, ed. Arthritis and allied conditions: a textbook of rheumatology. 11th ed. Philadelphia: Lea & Febiger, 1989: 507–43
   Google Scholar
• Brooks PM, Day RO. Plasma concentrations and therapeutic effects of anti-inflammatory and antirheumatic drugs. In: Lewis A, Furst DE, eds. Non-steroidal anti-inflammatory drugs: mechanisms and clinical use. New York: Marcel Dekker, 1987: 189–201
   Google Scholar
• Furst DE, Dromgoole SH. Indomethacin and sulindac. In: Paulus HE, Furst DE, Dromgoole SH, eds. Drags for rheumatic disease. New York: Longman (Churchill Livingstone), 1987: 285–314
   Google Scholar
• Blackshear JL, Davidman M, Stillman MT. Identification of risk for renal insufficiency from nonsteroidal anti-inflammatory drugs. Arch Intern Med 1983: 143(6): 1130–4
   PubMed Web of Science ®Google Scholar
• Brogden RN, Heel RC, Speight TM, et al. Tolmetin: a review of its pharmacological properties and therapeutic efficacy in rheumatic diseases. Drugs 1978: 15(6): 429–50
   PubMed Web of Science ®Google Scholar
• Lanza FL. Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin, and other nonsteroidal anti-inflammatory agents. Am J Med 1984: 77(1A): 19–24
   PubMed Web of Science ®Google Scholar
• Day RO, Furst DE, Graham GG, et al. Ibuprofen, fenoprofen, ketoprofen. In: Paulus et al, eds,10 pp 315–46
   Google Scholar
• Caldwell JR. Efficacy and safety of diclofenac sodium in rheumatoid arthritis: experience in the United States. Am J Med 1986: 80(4B): 43–7
   PubMed Web of Science ®Google Scholar
• Breen EG, McNicholl J, Cosgrove E, et al. Fatal hepatitis associated with diclofenac. Gut 1986: 27(11): 1390–3
   PubMed Web of Science ®Google Scholar
• Sanda M, Jacob GB, Fliedner L Jr, et al. Etodolic acid. In: Lewis, Furst, eds,9 pp 349–70
   Google Scholar
• Champion GD, Day RO, Graham GG. Drug interactions with non-steroidal anti-inflammatory drugs. In: Lewis, Furst, eds,9 pp 245–67
   Google Scholar
• Runkel R, Mroszczak E, Chaplin M, et al. Naproxen-probenecid interaction. Clin Pharmacol Ther 1978: 24(6): 706–13
   PubMed Web of Science ®Google Scholar
• Furst DE. Rational use of disease-modifying antirheumatic drags. Drugs (in press)
   Google Scholar
• Spector TD, Thompson PW, Evans SJ, et al. Are slow-acting antirheumatic drags being given earlier in rheumatoid arthritis? (Letter) Br J Rheumatol 1988: 27(6): 498–9
   PubMed Web of Science ®Google Scholar
• Wickens S, Paulus HE. Antimalarial drugs. In: Paulus et al, eds,10 pp 113–34
   Google Scholar
• Runge LA. Risk/benefit analysis of hydroxychloroquine sulfate treatment in rheumatoid arthritis. Am J Med 1983: 75(1A): 52–6
   PubMed Web of Science ®Google Scholar
• Bernstein HN. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med 1983: 75(1A): 25–34
   PubMed Web of Science ®Google Scholar
• Blocka K, Paulus HE. The clinical pharmacology of the gold compounds. In: Paulus et al, eds, 10 pp 49–83
   Google Scholar
• Cannon GW, Ward JR. Cytotoxic drugs and sulfasalazine. In: McCarty, ed,8 pp 563–92
   Google Scholar
• Skosey JL. Comparison of responses to and adverse effects of graded doses of sulfasalazine in the treatment of rheumatoid arthritis. J Rheumatol Suppl 1988: 16: 5–8
   PubMedGoogle Scholar
• Day RO, Paulus HE. D-penicillamine. In: Paulus et al, eds,10 pp 85–112
   Google Scholar
• Research Subcommittee of the Empire Rheumatism Council. Gold therapy in rheumatoid arthritis: a report of a multi-centre controlled trial. Ann Rheum Dis 1960: 19: 95–107
   PubMed Web of Science ®Google Scholar
• Singh G, Fries JF, Spitz P, et al. Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective. Arthritis Rheum 1989: 32(7): 837–43
   PubMed Web of Science ®Google Scholar
• Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985: 78(1A): 44–9
   PubMed Web of Science ®Google Scholar
• Furst DE, Kremer JM. Methotrexate in rheumatoid arthritis. Arthritis Rheum 1988: 31(3): 305–14 (Comment in: Arthritis Rheum 1989: 32[1]: 113–4)
   PubMedGoogle Scholar
• Furst DE, Koehnke R, Burmeister LF, et al. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989: 16(3): 313–20
   PubMed Web of Science ®Google Scholar
• Furst DE. Clinically important interactions of nonsteroidal antiinflammatory drags with other medications. J Rheumatol Suppl 1988: 17: 58–62
   PubMedGoogle Scholar
• Weinstein A. Long-term efficacy of methotrexate in rheumatoid arthritis. In: Wilke WS, ed. Methotrexate therapy in rheumatic disease. New York Marcel Dekker, 1989: 91–102
   Google Scholar
• Bunch TW, O'Duffy, Tompkins RB, et al. Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis. Arthritis Rheum 1984: 27(3): 267–76
   PubMedGoogle Scholar
• Garber EK, Targoff G Paulus HE. Corticosteroids in the rheumatic diseases: chronic low doses, chronic high doses, “pulses,” intra-articular. In: Paulus et al, eds,10 pp 443–76
   Google Scholar
• Ginzler E, Diamond H, Kaplan D, et al. Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum 1978: 21(1): 37–44
   PubMed Web of Science ®Google Scholar
• Radia M, Furst DE. Comparison of three pulse methylprednisolone regimens in the treatment of rheumatoid arthritis. J Rheumatol 1988: 15(2): 242–6
   PubMed Web of Science ®Google Scholar
• Jones JG. Avascular necrosis and pulsed methylprednisolone in RA. (Letter) Br J Rheumatol 1988: 27(6): 497–8
   PubMed Web of Science ®Google Scholar
• Bocanegra TS, Castaneda MO, Espinoza LR, et al. Sudden death after methylprednisolone pulse therapy. (Letter) Ann Intern Med 1981: 95(1): 122
   PubMed Web of Science ®Google Scholar